Lung cancer drug helps majority in study

	Tweet

An experimental drug to treat lung cancer appeared to benefit two-thirds of patients who used it, according to a study presented on Friday by manufacturer Telik Inc., pushing shares up as much as 17 percent.

The compound, Telcyta, aims to treat non-small cell lung cancer, one of the deadliest and poorly treated types of cancer.

Among 13 patients who took the medication along with a standard chemotherapy combination, seven experienced a partial response, and one patient had a complete response.

Results were presented at the American Society of Clinical Oncology meeting in Orlando, Florida.

Shares were up 35 cents, or 2.1 percent, at $17.35 in afternoon Nasdaq trade after rising as high as $19.87 earlier in the session. 

RELATED STORIES:
Lung cancer different in nonsmokers   What Is Lung Cancer?   Lung Cancer Linked To Gulf War Fires   Job exposure to pesticide linked to lung cancer   Lung Cancer: Glossary   False-positive cancer screening results costly   NY jury awards $17.1 million in sick smoker case   Spontaneous smoking cessation may be an early symptom of lung cancer, research suggests   Treatments boost lung cancer survival   New U.S. trial starts of tailored cancer treatment   What Causes Lung Cancer?   Advanced age no bar to lung cancer therapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]